This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Perini GF , Pro B
Brentuximab Vedotin in CD30+ Lymphomas
Biol Ther. 2013 ;3 :15-23
PMID: 24392301 PMCID: PMC3873074
AbstractMonoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin's lymphoma (cHL) and anaplastic large-cell lymphoma (ALCL). Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, utilizes the targeting properties of mAb to deliver a cytotoxic agent inside the malignant cell. Brentuximab vedotin has significant clinical activity in patients with relapsed or refractory cHL and relapsed or refractory ALCL, and has the potential to represent a significant advance in modern oncology.
NotesPerini, Guilherme Fleury Pro, Barbara REVIEW Biol Ther. 2013;3:15-23. Epub 2013 Mar 1.